Apr 07, 2009 - 4:35 AM EDT
Jessica Johnson submits:Immucor (BLUD), a provider of automated instrument-reagent systems to the blood transfusion industry, announce their Q3 reults on Monday with a conference call on Tuesday to discuss the results. According to Schaeffersresearch.com, pessimism appears to be on the rise for this stock. In short selling terms, investors have increased their positions in this company since March 16, when BLUD had 2.2% of its shares on loan, to the current figure of 3.5%, as you can see from this graph. This figure has, however, decreased since January 30, from the 3.7% mark. The company's share price has dropped from $30 to $24 over the last six months.
Click to enlarge:
Source: Seeking Alpha (Apr 07, 2009 - 4:35 AM EDT)